CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM closes another product portfolio acquisition

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of cardiologic diseases. The acquisition was signed in June 2020 with one of Cheplapharm´s long standing partners. The APIs of the referring products are Colesevelam, Molsidomine, Acebutolol, Nadolol, Propranolol and Sotalol. The asset deal contains product registrations, intellectual property, certain contracts and inventory mainly valid for European Countries. The deal does not include any transfer of manufacturing facilites or employees.

“This investment underlines the value of our platform enabling us  to further integrate products in our portfolio”, said CHEPLAPHARM´s CEO Sebastian F. Braun.

Investor Relations topics

Back to top expand_less